

PCI Investigator-Sponsored Research¹


RECHARGE ▪ Registry of CrossBoss and Hybrid Procedures



Clinical validation of
efficacy & efficiency of the
Hybrid Algorithm & the
use of CrossBoss™ and
Stingray™ technologies.

Principal Investigator:
Prof. Dr. Jo Dens


OPEN CTO ▪ Outcomes, Patient Health Status, and Efficiency in CTOs



Safety & Effectiveness of
Hybrid Algorithm &
CrossBoss and Stingray
Technologies

Principal Investigator:
J. Aaron Grantham, MD


CrossBoss First ▪ Randomized Comparison of CrossBoss First vs. Standard Wire Escalation for Crossing CTOs



Efficacy objective: compare procedure time required to
cross CTO or abort procedure with CrossBoss first vs.
antegrade wire escalation. Safety objective: compare
frequency of procedural MACE with upfront use of
CrossBoss vs. guidewire escalation.

Principal Investigator:
Emmanouil Brilakis, MD


CONSISTENT CTO ▪ Safety And Efficacy of Sub-Intimal Stenting with SYNERGY in CTO



Prospective, multi-center,
single arm

Principal Investigator:
Simon Walsh, MD


OPTIMUM ▪ A Prospective Registry



Outcomes of Percutaneous
Revascularization or Medical
Therapy for Surgically Ineligible
Patients with Multivessel or Left
Main Coronary Artery Disease

Principal Investigator:
J. Aaron Grantham, MD

SYNTAX II ▪ Multi-Vessel Disease



SYNERGY Stent single arm, compared
to historical CABG population;
IVUS and FFR to be utilized

Principal Investigator:
Javier Escaned, MD

IDEAL LM ▪ Left Main European RCT



SYNERGY Stent vs. Xience™
Stent, (RCT 1:1); OCT healing
substudy at 3-months

Principal Investigator:
Robert-Jan van Geuns, MD

CELTIC BIFURCATION ▪ Coronary Bifurcation Study (Culottes Bifurcation Stenting)



SYNERGY Stent vs. Xience
Xpedition™ Stent (RCT 1:1)

Principal Investigator:
David Foley, MD


SENIOR ▪ Reduced DAPT in Elderly



SYNERGY Stent vs. BMS
1-month DAPT in elective
patients and 6-months DAPT
in ACS patients (RCT 1:1)

Principal Investigator:
Olivier Varenne MD, PhD

BIORESORT ▪ All Comers with Diabetes Substudy



SYNERGY Stent vs.
Resolute Integrity™ Stent vs.
Orsiro™ Stent (RCT 1:1:1)

Principal Investigator:
Clemens von Birgelen,
MD, PhD

1. Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific's involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about our products. Safety and performance of the SYNERGY Coronary Stent System has not been established for use in patients with STEMI, Left Main, chronic total occlusion, bifurcation and multi-vessel disease stenting. The SYNERGY Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions.

2. For the SYNTAX II study, MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization.

3. For the CELTIC BIFURCATION Study Clinical and Angiographic composite is defined as: Death, Myocardial Infarction, CVA (cerebrovascular events), Target Vessel Failure (Composite of Target Vessel Revascularization and Target Vessel Inadequacy); Definite or Probable stent thrombosis (ARC criteria); Binary angiographic restenosis.

4. For the IDEALLM study, MACCE is defined as: all-cause death; stroke; myocardial infarction or ischemia driven target vessel revascularization.

5. Target Vessel Failure is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or cardiac death.